Congress creates public health plan, mandates provider participation

What it does

This bill establishes a new public health insurance plan called Medicare-X that would be available to individuals and small businesses starting in 2028, operating through existing ACA exchanges. The plan would reimburse providers at Medicare rates, cover primary care with no cost-sharing, and be funded by premiums designed to cover full actuarial costs plus $2 billion in startup funding. The bill also expands ACA tax credits, allows Medicare to negotiate drug prices, and funds antitrust enforcement in health care markets.

Why we flagged it

The bill's core mechanism is the creation and operation of a government-administered health plan competing in the individual and small-group markets. While it includes ancillary provisions on drug negotiation and antitrust enforcement, the functional center is a public insurance option—a direct market intervention.

What the text implies

• Mandatory provider participation (Section 2208) creates a de facto universal network requirement: providers cannot participate in Medicare or Medicaid without also joining Medicare-X, potentially forcing smaller practices into the plan regardless of profitability concerns.
• Risk-pool design (Section 2206) allows separate pools by market and state, which could enable adverse selection if sicker individuals concentrate in the public plan, requiring ongoing premium adjustments or subsidies.
• Reinsurance program (Section 4) pools high-cost patients across all individual market plans, potentially shifting costs from private insurers to federal budget if the public plan attracts disproportionately sick enrollees.
• Drug negotiation authority (Section 6) removes a statutory cap on Medicare's negotiating power, potentially reducing pharmaceutical company revenues and affecting drug development incentives long-term.
• Antitrust funding (Section 7) signals intent to challenge provider consolidation and market power, which may disrupt existing health system arrangements and increase litigation risk for large hospital systems.

Who it affects

Ordinary citizens gain access to a lower-cost insurance option with free primary care, expanded tax credits making coverage more affordable for middle-income families, and Medicare drug price negotiation. While the plan's long-term sustainability depends on enrollment and cost management, the immediate effects—lower premiums, reduced cost-sharing, and broader subsidy eligibility—benefit consumers. Providers face mandatory participation requirements, but this is offset by stable Medicare-rate rei

Who stands to gain

• Individual consumers (lower premiums, expanded subsidies)
• Small businesses (access to competitive group plan)
• Primary care providers (guaranteed Medicare-rate reimbursement)
• Rural providers (up to 50% payment increase)

Named in the bill

Department of Health and Human Services (HHS), Centers for Medicare & Medicaid Services (CMS), Social Security Administration, Department of Justice Antitrust Division, Federal Trade Commission (FTC), Bristol Myers Squibb (BMY), Grifols (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ), American Health Benefit Exchanges, State insurance commissioners — and 2 more

Where it stands

2 cosponsors: 2 Democrats.

• Jul 15, 2026 — Introduced · Congress.gov: “Introduced in House”
• Jul 15, 2026 — Referred to House Committee on the Judiciary and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.